Warning signs were always there for Novartis’s Avexis deal
High-profile departures at Avexis raise more questions about Novartis’s acquisition, but there were plenty of red flags before the deal was sealed.
Shikeda masks slow second quarter for buyouts
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
Blockbuster approvals line up for biopharma in 2018
2018 shaping up to be a bumper approval year, as Juno Therapeutics, Epizyme and Avexis line up to launch potential blockbusters.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
